From the ∗Mayo Clinic Cancer Center, Division of Medical Oncology, Rochester, MN
†Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL
‡Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
§Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA
∥Department of Medicine, University of California, San Francisco, San Francisco, CA
¶Department of Medicine, Division of Endocrinology, University of Iowa Carver College of Medicine, Iowa City, IA
#Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX
∗∗Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, Division of Biomedical Informatics and Personalized Medicine, University of Colorado School of Medicine, Aurora, CO
††Division of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
‡‡Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA
§§Department of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
∥∥Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago IL
¶¶Division of Gastroenterology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
##Banner MD Anderson Cancer Center, Gilbert, AZ
∗∗∗Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
†††Department of Surgery, University of Iowa Carver College of Medicine, Iowa City, IA
§§§Department of Surgery, Oregon Health and Science University, Portland, OR
∥∥∥Department of Radiology, University of Iowa Carver College of Medicine, Iowa City, IA
¶¶¶Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Received for publication April 24, 2020; accepted May 20, 2020.
Address correspondence to: Thorvardur R. Halfdanarson, MD, Mayo Clinic Cancer Center, 200 First St SW, Rochester, MN 55905 (e-mail: [email protected]).
T.R.H. has received consulting fees from Ipsen, Advanced Accelerator Applications, Lexicon, Curium, and TERUMO, and research support from Thermo Fisher Scientific, and Ipsen. J.R.S. has received consulting fees from Novartis, and is a member of the speaker's bureau of Lexicon and Ipsen. E.K.B. has received research support from Novartis and Merck and consulting fees from AAA, Ipsen, and Hutchison MediPharma (all unpaid). D.M.H. has received consulting fees from Ipsen, Advanced Accelerator Applications, Lexicon, Novartis, AbbVie, and Curium, and research support from Genentech/Roche, Tarveda Therapeutics, Thermo Fisher Scientific, Incyte, Lexicon, and Advanced Accelerator Applications. J.E. has received consulting fees from Lexicon (ongoing), Novartis (within the past 2 years), has an employment status in Bristol Meyers Squibb (spouse), has stocks in Bristol Meyers Squibb (pending), and has received honoraria from Pfizer (talk). T.A.H. has received consulting fees from and is a member of the advisory board of Ipsen, and Curium; has received research support from Clovis Oncology, Philips, and Advanced Accelerator Applications. S.S. has received consulting fees from Novartis and Ipsen and research support from Novartis. R.S. has received consulting fees from Cook, Boston Scientific, Genentech, Eisai, and Becton-Dickinson. D.C.M. has received consulting fees from Ipsen, Advanced Accelerator Applications, Lexicon, Wren Laboratories, and Intercept. B.G.N. has received consulting fees from Advanced Accelerator Applications, Lexicon, and Novocure. D.L.R.-L. has received consulting fees from Advanced Accelerator Applications, Lexicon, and Bind Insurance, and research support from Merck, Ipsen, and Novartis. R.F.P. has received consulting fees from Ipsen, Advanced Accelerator Applications, Lexicon, and Novartis, is a member of the speaker's bureau of Novartis. Y.M. has received consulting fees from Progenics Pharmaceuticals and Advanced Accelerator Applications. J.A.C. has received consulting fees from Crinetics, Ipsen, Novartis, and Lexicon (spouse has consulted for Bayer and Pfizer); has received royalties from UpToDate; and has stocks in Merck. L.T., A.M.B., T.M.O., L.F., and J.R.H. declare no conflict of interest.
